The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Shares are up more than 50% already this year, as the story surrounding the company’s GLP-1 drugs gets better and better.

Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

Eli Lilly (LLY) expects to start selling its weight-loss drug tirzepatide, branded as Mounjaro, in Hong Kong as early as the ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, ...

Oct 27 (Reuters) - Eli Lilly (LLY.N), opens new tab expects to start selling its weight-loss drug in Hong Kong as early as ...

(Bloomberg) -- Eli Lilly & Co. expects to start selling its highly popular weight-loss drug in Hong Kong as early as the end ...

Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...

Eli Lilly to Introduce Mounjaro Weight-Loss Drug in Hong Kong by Year-End Global pharmaceutical giant Eli Lilly is gearing up ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug ...